NIPRO (8086) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Operating income and ordinary income grew faster than revenue, resulting in earnings driven by improved profitability. Revenue remained limited to ¥4,873.1B (+1.7% YoY), while operating income increased to ¥267.5B (+20.5%) and ordinary income to ¥176.1B (+25.7%), with profit growth outpacing revenue growth. Net income rose substantially to ¥183.2B (+130.2% YoY), but this largely reflected temporary factors, including ¥145.2B in extraordinary gains such as a gain on step acquisitions and gains on sales of fixed assets; this should therefore be distinguished from recurring earnings growth.

Factors Affecting Earnings

【Revenue】Revenue was ¥4,873.1B, representing only a modest 1.7% increase YoY. By segment, the core Medical-Related Business remained solid at ¥3,936.5B (80.8% of total revenue), while the Pharmaceutical-Related Business remained broadly flat at ¥1,045.4B. Pharma Packaging declined 12.5% YoY, weighing on overall growth.

【Profit and Loss】Operating income increased to ¥267.5B (+20.5% YoY), substantially outpacing revenue growth, and the operating margin reached 5.5%. Improvement in the Medical-Related Business’s profit margin and an increase in the Pharmaceutical-Related Business’s profit margin to 14.9% were the main drivers. In contrast, Pharma Packaging fell into a segment loss of ¥14.8B and also recorded ¥6.5B in goodwill impairment. Ordinary income was ¥176.1B (+25.7% YoY), while the ¥106.4B difference from profit before tax of ¥282.4B was primarily attributable to extraordinary gains, including a ¥44.8B gain on the sale of fixed assets and gains on step acquisitions. Net income increased substantially to ¥183.2B, but a considerable portion of the increase depended on temporary factors. Accordingly, despite higher revenue and profits, the quality of earnings growth should be assessed based on operating income and ordinary income.

Segment Analysis

The Medical-Related Business generated revenue of ¥3,936.5B (+3.7% YoY) and operating income of ¥375.2B (+3.1% YoY), maintaining a profit margin of 9.5%. It is the core business, generating more than 80% of total segment profit. The Pharmaceutical-Related Business remained almost flat, with revenue of ¥1,045.4B (-0.2% YoY), but operating income rose substantially to ¥88.1B (+35.8% YoY), improving its profit margin to 8.4%. Pharma Packaging’s revenue declined 12.5% YoY, and the business fell into an operating loss of ¥14.8B, compared with profit of ¥5.2B in the same period of the previous year. It also recorded ¥6.5B in goodwill impairment, indicating a pronounced deterioration in profitability. Corporate expenses increased 3.8% YoY to ¥200.2B, but profit growth in the Medical-Related and Pharmaceutical-Related Businesses absorbed these costs and contributed to the expansion of consolidated operating income.

Key Financial Indicators

【Profitability】The operating margin improved to 5.5% from 4.6% in the same period of the previous year, while the net profit margin also increased to 3.4% on a basis attributable to owners of the parent. However, it should be noted that the increase in the net profit margin includes the contribution of extraordinary gains and losses. The gross margin was 31.0%, and the SG&A expense ratio was 25.6%.【Cash Flow Quality】Accounts receivable of ¥1,720.3B and inventories of ¥1,793.5B indicate a substantial working capital investment. On an annualized basis, accounts receivable collection days and inventory turnover days have tended to lengthen, requiring ongoing monitoring of whether improved earnings are being sufficiently converted into cash.【Investment Efficiency】ROE was 5.8% on a disclosed basis. Against total assets of ¥11,999.0B, revenue was ¥4,873.1B, indicating a low asset turnover ratio. The asset-intensive structure, including ¥4,949.7B in property, plant and equipment, is constraining capital efficiency.【Financial Soundness】The equity ratio was 26.2%. Current assets of ¥5,925.3B versus current liabilities of ¥4,340.4B resulted in a current ratio of approximately 136%. Interest-bearing debt remained high, including ¥2,796.8B in long-term borrowings and ¥1,037.9B in bonds, indicating an earnings structure that utilizes financial leverage.

Cash Flow Analysis

Although no cash flow statement has been disclosed, funding conditions are analyzed based on balance sheet trends. Cash and deposits increased to ¥1,124.2B from ¥1,066.7B in the previous year, while short-term borrowings expanded to ¥1,895.2B from ¥1,561.7B, suggesting that part of working capital is being financed through short-term borrowings. Accounts receivable of ¥1,720.3B and inventories of ¥1,793.5B were both high, and the substantial difference from accounts payable of ¥813.2B suggests that funds remain tied up in working capital for an extended period. While operating income continues to improve, reducing this working capital investment will be a key focus for improving funding efficiency going forward.

Quality of Earnings

Both recurring and temporary factors contributed to earnings growth during the current period. The increases in operating income and ordinary income reflect recurring improvements in earning power resulting from better profitability in the Medical-Related and Pharmaceutical-Related Businesses. In contrast, the substantial increase in net income (+130.2% YoY) was primarily attributable to ¥145.2B in extraordinary gains, including a ¥44.8B gain on the sale of fixed assets and gains on step acquisitions. Extraordinary losses of ¥38.9B also arose concurrently, including ¥6.5B in goodwill impairment in Pharma Packaging. Among non-operating items, interest expenses of ¥69.3B accounted for the bulk of non-operating expenses, with financing costs weighing on ordinary income. Comprehensive income was ¥75.7B, substantially below net income of ¥183.2B, primarily due to a foreign currency translation adjustment of -¥105.7B. The divergence between comprehensive income and net income indicates that foreign exchange movements in overseas operations have a significant impact on the company’s financial position.

Earnings Forecast and Guidance

Progress against the full-year plan was 72.0% for revenue, 72.3% for operating income, and 72.8% for ordinary income, slightly below the standard nine-month progress rate of 75%. Meanwhile, net income attributable to owners of the parent was already ¥166.8B against the full-year plan of ¥129.5B, reaching 128.8%. However, this was attributable to the recognition of extraordinary gains and should be evaluated separately from operating progress. Achieving the full-year operating income plan of ¥370.0B (+39.1% YoY) will depend on continued revenue growth in the Medical-Related Business and an improvement in Pharma Packaging’s profitability during Q4.

Shareholder Returns

The Q2 dividend was ¥10.00 per share, and the full-year forecast dividend is ¥28.00. The implied year-end dividend, calculated from the interim actual dividend, is ¥18.00. Based on the company’s full-year forecast net income attributable to owners of the parent of ¥129.5B, the forecast payout ratio is approximately 35.3%, below the generally used sustainability benchmark of 60%. However, because the excess of cumulative Q3 net income over plan was largely attributable to extraordinary gains, the dividend funding capacity should appropriately be assessed based on sustainable levels of operating income and ordinary income.

Risk Factors

1. Deterioration in Pharma Packaging profitability: Revenue declined 12.5% YoY, resulting in a segment loss of ¥14.8B, while ¥6.5B in goodwill impairment was also recorded. If demand recovery or profitability improvement is delayed, the possibility of additional impairment represents a concern.

2. Financial leverage and reliance on short-term funding: The D/E ratio remains high, and short-term borrowings of ¥1,895.2B exceed cash and deposits of ¥1,124.2B. Together with an equity ratio of 26.2%, the impact of changes in the interest-rate environment on financing costs should be monitored.

3. Prolonged working capital cycle: Working capital is substantial, with accounts receivable of ¥1,720.3B and inventories of ¥1,793.5B. Continued monitoring is required to determine whether improved earnings are being sufficiently translated into cash generation. Particular attention should be paid to the risk of inventory accumulation and valuation losses, especially for products totaling ¥1,793.5B.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

The company’s profitability is below the industry median and is positioned at a level with room for improvement compared with the manufacturing industry average.

Growth and Capital Efficiency

Revenue growth also slightly underperformed the industry median, with profit growth achieved primarily through improved profitability.

※Source: Compiled by the company

Key Points in the Earnings Results

1. Operating income is expanding at a pace substantially exceeding revenue growth, with improved profitability in the Medical-Related and Pharmaceutical-Related Businesses driving up the company-wide profit margin. Meanwhile, Pharma Packaging experienced declining revenue and turned loss-making, while also recording goodwill impairment. The widening profitability gap among businesses is a notable characteristic of the earnings structure.

2. The substantial increase in net income was largely attributable to extraordinary gains and losses, including gains on the sale of fixed assets and gains on step acquisitions. Comprehensive income of ¥75.7B was substantially below net income of ¥183.2B, primarily due to the negative foreign currency translation adjustment. Operating income and ordinary income are therefore the appropriate bases for assessing recurring earnings levels.

3. The company has a financial structure characterized by substantial working capital, primarily accounts receivable and inventories, and a high reliance on short-term borrowings. Operating income progress against the full-year plan was 72.3%, generally progressing steadily. The performance of the core businesses in Q4 and improved working capital efficiency will be the key areas of focus going forward.

Theoretical Share Price (For Reference)

Sensitivity: ¥1,631–¥1,726 at ±1% for the cost of equity, and ¥1,669–¥1,683 at ±0.1 for ω.

Notes:

• Because net income progress against the full-year forecast (129%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies progressing ahead of plan tend to outperform forecasts; adjustments may be excessive for businesses with strong seasonality).
• Net income is substantially compressed relative to operating income due to tax burdens, acquisition-related expenses, and non-controlling interests, among other factors (net income ÷ operating income 35%). This figure reflects that compression as reported, and underlying earnings power could be higher if these factors are temporary.
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end have been used; there is a timing difference from the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Nipro delivered a stronger FY2026 Q3 cumulative operating result, although reported net income was materially supported by non-recurring gains and balance-sheet leverage remains elevated. Revenue increased 1.7% year on year to ¥487.3bn. Operating income increased 20.5% to ¥26.7bn, substantially outpacing sales growth. Ordinary income rose 25.7% to ¥17.6bn despite a ¥6.9bn interest-expense burden. Profit attributable to owners of the parent surged 153.0% to ¥16.7bn. Gross margin expanded by approximately 65bp to 31.0%, from 30.4% in the prior-year period. The SG&A-to-sales ratio declined by approximately 21bp to 25.6%. Consequently, operating margin improved by approximately 86bp to 5.5%, from 4.6%. Medical-related operations remained the earnings core, generating segment profit of ¥37.5bn. Pharmaceutical operations also improved, with segment profit rising to ¥8.8bn. In contrast, pharma packaging moved to a ¥1.5bn segment loss from a ¥0.5bn profit. Consolidated net margin improved to 3.4% from 1.4%, but this improvement overstates underlying recurring progress because extraordinary income totaled ¥14.5bn. The principal non-recurring contributors included a ¥5.2bn gain on step acquisitions, a ¥4.5bn gain on fixed-asset sales, and ¥2.3bn of state subsidies. These gains were partly offset by ¥2.1bn of losses on reduction of non-current assets and ¥0.7bn of impairment, including a pharma-packaging goodwill impairment. The full-year operating-income forecast of ¥37.0bn implies that the company has achieved 72.3% of target after nine months, modestly below the standard 75% seasonal run rate. Full-year net income guidance of ¥13.0bn has already been exceeded by Q3 cumulative attributable profit, indicating that the forecast embeds substantial Q4 non-recurring reversals, expenses, or conservatism. The investment debate is therefore centered on whether medical-related margin improvement can continue while the company improves working-capital discipline, restores pharma-packaging profitability, and deleverages its acquisition-supported capital structure.

Profitability Analysis

The reported annualized ROE is 7.1%, below the 8% threshold generally associated with adequate capital efficiency. The DuPont decomposition is annualized net profit margin of 3.4% multiplied by annualized asset turnover of 0.541x and financial leverage of 3.81x. Financial leverage is the dominant support for ROE, while modest margins and low asset turnover constrain returns on the underlying asset base. The operating-margin improvement to 5.5% was the main recurring profitability improvement, reflecting gross-margin expansion and a modest reduction in SG&A intensity. Revenue growth of 1.7% was well below operating-income growth of 20.5%, demonstrating favorable operating leverage. Gross profit increased 3.8% to ¥151.3bn, while SG&A increased only 0.8% to ¥124.6bn. The medical-related segment is the core business by operating-income contribution, with external sales of ¥388.0bn, up 3.7% year on year, and segment profit of ¥37.5bn, up 3.1%. Its segment margin was 9.5%, broadly stable versus 9.6% a year earlier. Pharmaceutical external sales were ¥59.0bn, down 0.2%, while segment profit increased 35.8% to ¥8.8bn and segment margin improved to 14.9% from 11.0%. Pharma packaging external sales declined 12.5% to ¥39.5bn and segment performance deteriorated to a ¥1.5bn loss from a ¥0.5bn profit, creating a negative 3.7% margin. Corporate and consolidation adjustments improved to negative ¥18.9bn from negative ¥21.2bn, helping consolidated operating profit. Interest coverage was 3.86x, adequate but below the level associated with a strong debt-service cushion. The annualized 3.4% net margin is still modest for the company’s asset intensity, and the ¥10.1bn net extraordinary gain means that the 153% increase in attributable profit is not representative of recurring earnings power. Under JGAAP, goodwill amortization and impairment can depress operating and net income relative with IFRS reporters; the disclosed ¥0.7bn impairment confirms that acquired businesses require ongoing value-retention monitoring.

Growth Assessment

The sales trajectory is subdued, with consolidated revenue rising only 1.7% year on year to ¥487.3bn. Medical-related sales growth of 3.7% supported the overall result and reinforces its role as the principal growth engine. Pharmaceutical sales were essentially flat, while pharma packaging contracted materially. Segment mix therefore became less favorable in the packaging business, despite consolidated margin expansion. The full-year revenue forecast is ¥677.0bn, and Q3 cumulative sales represent 72.0% of that target, 3.0 percentage points below the standard 75% Q3 progress rate but not a material deviation. Full-year operating-income forecast progress is 72.3%, similarly modestly below the standard run rate. Ordinary-income progress is 72.8% against the ¥24.2bn forecast. The forecast calls for 5.0% full-year sales growth and 39.1% operating-income growth, requiring a stronger Q4 revenue and margin outcome than the nine-month pace. Attributable profit has reached 128.8% of the ¥13.0bn full-year forecast, but this is driven by gains on step acquisitions, fixed-asset sales, and subsidies rather than a commensurate rise in operating earnings. The ¥6.5bn impairment in the pharma-packaging segment’s goodwill is a signal that this business requires a recovery in operating performance to validate its asset base. Seven subsidiaries were newly consolidated during the period, consistent with the sharp increase in goodwill and intangible assets and adding integration execution risk. Construction in progress of ¥95.1bn, equal to 19.2% of PPE, indicates an active manufacturing investment pipeline. Future growth quality should be judged by medical-related volume and margin delivery, stabilization of pharma packaging, and the return generated from newly consolidated businesses and ongoing plant investments.

Financial Health

Liquidity is acceptable but not strong for a highly leveraged manufacturer. The current ratio is 136.5%, above 1.0x, so current assets exceed current liabilities and there is no immediate current-ratio warning. However, the quick ratio is 95.2%, below 1.0x, meaning liquidity depends partly on inventory conversion. Working capital is ¥158.5bn. Interest-bearing debt is ¥469.2bn, equivalent to 2.81x total equity, and this exceeds the 2.0x high-leverage warning threshold. Debt-to-capital is 59.9%, close to the 60% covenant-risk benchmark and indicative of debt-led financing. Short-term loans are ¥189.5bn, while current liabilities total ¥434.0bn. The short-term debt ratio is 40.4%, marginally above the refinancing-risk threshold and requires regular funding-market access. Cash and deposits of ¥112.4bn cover only 0.59x of short-term loans, limiting the ability to repay near-term borrowings solely from on-balance-sheet cash. Long-term loans of ¥279.7bn and bonds payable of ¥103.8bn provide a meaningful longer-term funding base, but interest expense rose 22.3% year on year to ¥6.9bn. The high-leverage quality alert reflects aggressive balance-sheet financing relative to equity; it amplifies returns when profitability improves but also increases sensitivity to rates, refinancing conditions, and earnings volatility. The refinancing-risk alert is relevant because a large proportion of borrowings is short-term; this structure is not unusual for working-capital-intensive manufacturing groups, but the long conversion cycle makes it more consequential. Owners’ equity is ¥255.0bn and the equity ratio is 21.3%, slightly lower than 21.6% a year earlier. Goodwill is ¥37.5bn, or 11.9% of total equity and 3.1% of assets, which is well below the 30% and 50% M&A-risk thresholds. Intangible assets are ¥57.2bn, or 4.8% of assets, also a contained level. No material off-balance-sheet obligation is indicated by the available balance-sheet information; lease obligations total ¥30.4bn across current and non-current liabilities.

Notable B/S Changes

Goodwill: +¥234.4bn (+166.2%) to ¥375.4bn - reflects acquisition and newly consolidated-business effects; the 11.9% goodwill-to-equity ratio is currently moderate, but the ¥0.7bn pharma-packaging impairment makes integration and future impairment performance material. Intangible assets: +¥217.2bn (+61.2%) to ¥572.3bn - consistent with acquisition-related asset recognition and raises the importance of earnings delivery from acquired technologies, customer relationships, and businesses. Short-term loans: +¥333.4bn (+21.4%) to ¥1,895.2bn - an absolute increase above ¥50bn that increases refinancing dependence, particularly given cash coverage of only 0.59x of short-term debt. Long-term loans: -¥303.0bn (-9.8%) to ¥2,796.9bn - indicates a shift in debt composition toward shorter maturities rather than a material reduction in overall leverage. Current liabilities: +¥835.0bn (+23.8%) to ¥4,340.4bn - a large absolute increase that reinforces the need to monitor short-term funding and working-capital monetization. Construction in progress: +¥61.5bn (+6.9%) to ¥951.3bn - represents 19.2% of PPE and signals a substantial manufacturing investment pipeline; timely completion and adequate returns are important.

Cash Flow Quality

Cash-flow conversion cannot be assessed directly from the available cumulative cash-flow figures, so no OCF-to-net-income or free-cash-flow coverage conclusion is drawn. Earnings quality is nevertheless constrained by the composition of pre-tax profit. Profit before tax was ¥28.2bn, substantially above ordinary income of ¥17.6bn because extraordinary income exceeded extraordinary losses by ¥10.1bn. The high-one-time-items alert, which identifies non-recurring items at 31.4% of net income, is therefore material: gains on step acquisitions, fixed-asset sales, and subsidies enhanced reported earnings but are not a recurring source of cash generation. The ¥0.7bn impairment charge, including ¥0.7bn in pharma packaging goodwill impairment, partly offsets those gains and points to acquisition-value risk. Working-capital efficiency is a central cash-quality concern. Annualized receivable days are 97 days, above the 60-day warning level, indicating slow cash collection relative to manufacturing benchmarks. The high-receivable-days alert raises the risk that accounting earnings convert into cash more slowly, especially if sales conditions weaken. Inventory days are flagged at 146 days and 213 days under the reported alternative inventory calculations; both measures are well above the applicable 60- to 90-day warning thresholds. Finished goods are ¥179.3bn, while raw materials are ¥58.7bn and work in process is ¥23.3bn, indicating a significant finished-goods inventory concentration. The high-inventory-days alerts suggest elevated holding-cost, demand-forecasting, and obsolescence risk, particularly in the loss-making pharma-packaging operation. The reported annualized cash conversion cycle of 243 days is substantially above the 120-day warning threshold. This long-CCC alert is important because debt-funded working capital can absorb liquidity and increase refinancing dependence. Accounts payable of ¥81.3bn do not fully offset the cash tied up in receivables and inventories. Improving collections, aligning production with demand, and reducing finished-goods inventory are key requirements for better cash earnings quality.

Dividend Sustainability

The disclosed interim dividend is ¥10.0 per share. The current calculated dividend payout ratio is 10.3%, which is low relative to reported nine-month earnings and provides a substantial accounting earnings buffer. The full-year dividend forecast is ¥28.0 per share, implying a prospective payout ratio of approximately 35.3% against forecast EPS of ¥79.4. This prospective payout remains below the 60% sustainability benchmark. Retained earnings increased 12.3% year on year to ¥117.7bn, providing an additional balance-sheet buffer. However, the strong Q3 attributable-profit figure includes material non-recurring gains and should not be treated as recurring dividend capacity. Debt-to-equity of 2.81x, cash coverage of only 0.59x for short-term loans, and the long cash conversion cycle mean that deleveraging and working-capital funding compete with shareholder distributions for internally generated cash. Dividend sustainability is therefore better supported by the low indicated payout than by the quality of Q3 net income. The outlook for the ¥28 per share annual dividend depends on delivery of the recurring operating-income forecast, maintenance of bank and capital-market funding access, and improvement in working-capital cash absorption.

Risk Assessment

Business risks include Pharma packaging generated a ¥1.5bn segment loss versus a ¥0.5bn profit a year earlier, alongside a 12.5% decline in external sales; continued deterioration could offset gains in medical-related and pharmaceutical operations., Medical-related operations account for the majority of external sales and segment profit, creating concentration risk to demand conditions, reimbursement environments, hospital procurement patterns, product quality, and regulatory compliance in the medical-device market., Inventory days are flagged at 146 to 213 days and finished goods total ¥179.3bn, increasing risk of inventory obsolescence, pricing pressure, and production-demand mismatch., A ¥0.7bn impairment in pharma-packaging goodwill indicates that acquired-business performance and integration outcomes require monitoring., The manufacturing footprint is exposed to raw-material, energy, logistics, foreign-exchange, quality-control, and product-recall risks; foreign-exchange gains of ¥1.6bn also show that non-operating earnings can be affected by currency movements..

Financial risks include D/E of 2.81x exceeds the 2.0x warning threshold, while debt-to-capital of 59.9% is near the 60% concern level; leverage is the principal support to the 7.1% annualized ROE but increases downside sensitivity., Short-term loans of ¥189.5bn represent 40.4% of debt, marginally above the refinancing-risk threshold, while cash covers only 0.59x of short-term debt., Interest expense of ¥6.9bn exceeds interest income of ¥1.6bn, and 3.86x interest coverage leaves a limited cushion against higher borrowing costs or weaker operating income., Receivable days of 97 and a reported 243-day annualized cash conversion cycle expose liquidity to delayed collections and inventory monetization., Comprehensive income of ¥7.6bn was well below net income of ¥18.3bn because other comprehensive income was negative, including foreign-currency translation effects..

Key concerns include The high-tax-burden alert is relevant because the reported tax burden is 0.591, below the 0.60 warning threshold. The reported income-tax expense is ¥9.9bn, and the tax burden is also affected by profit attributable to non-controlling interests; it reduces the conversion of pre-tax income to parent earnings. The stated 35.1% effective tax rate is elevated but below 40%, so ongoing tax normalization remains important rather than assuming a structural 41% rate., The capital-efficiency alert reflects annualized ROIC of 3.4%, below the 5% warning threshold. This suggests operating returns remain insufficient relative to the capital employed in PPE, working capital, and acquisitions, notwithstanding the improvement in operating margin., The high-one-time-items alert is material because extraordinary gains lifted profit before tax; recurring operating income of ¥26.7bn is the more appropriate base for assessing sustainable earnings., The duplicate high-inventory-days alerts, at 146 and 213 days, point in the same direction despite differing reported inventory definitions: inventory intensity is high and should be reduced through demand planning and production discipline., The most important indicators to monitor are pharma-packaging recovery, receivable and inventory days, short-term debt refinancing, interest coverage, and recurring operating-margin progression..

Investment Implications

Key takeaways include Operating profit growth of 20.5% materially exceeded 1.7% revenue growth, supported by an approximately 86bp operating-margin expansion to 5.5%., Medical-related operations are the core business, producing ¥37.5bn of segment profit, while pharmaceutical profitability improved sharply., Pharma packaging is the principal operating weak spot, with a ¥1.5bn segment loss and a related ¥0.7bn goodwill impairment., Reported attributable profit of ¥16.7bn was substantially enhanced by extraordinary gains, limiting comparability with recurring earnings., High leverage, a 243-day reported cash conversion cycle, and short-term debt dependence make working-capital release and refinancing management strategically important., Goodwill and intangible-asset ratios remain moderate despite their sharp year-on-year increase, reducing near-term balance-sheet concentration risk relative to highly acquisitive peers..

Metrics to watch include Medical-related segment sales growth and segment margin, Pharma-packaging sales, return to segment profitability, and further impairment charges, Consolidated operating margin versus the 5.5% Q3 cumulative level, Receivable days of 97, inventory days of 146 to 213, and the reported 243-day annualized cash conversion cycle, Short-term debt ratio of 40.4%, cash-to-short-term-debt ratio of 0.59x, and interest coverage of 3.86x, Annualized ROIC of 3.4% and annualized ROE of 7.1%, Progress toward full-year sales of ¥677.0bn, operating income of ¥37.0bn, and the ¥28 per share dividend forecast.

Regarding relative positioning, Nipro combines a defensible medical-related earnings base and improving operating leverage with below-target capital efficiency, more aggressive leverage than conservatively financed manufacturing peers, and unusually extended working-capital intensity. Its goodwill-to-equity ratio of 11.9% is comparatively moderate, but its annualized ROIC of 3.4%, D/E of 2.81x, and reported 243-day cash conversion cycle leave it more dependent on execution and funding discipline than higher-margin, faster-converting peers.